Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium

Authors
Lee, Han AhRim, Chai Hong
Issue Date
2020
Publisher
DOVE MEDICAL PRESS LTD
Keywords
hepatocellular carcinoma; inferior vena cava; right atrium; surgery; radiotherapy
Citation
JOURNAL OF HEPATOCELLULAR CARCINOMA, v.7, pp.435 - 446
Indexed
SCIE
Journal Title
JOURNAL OF HEPATOCELLULAR CARCINOMA
Volume
7
Start Page
435
End Page
446
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/59039
DOI
10.2147/JHC.S285357
ISSN
2253-5969
Abstract
Major vessel invasion is frequently observed in locally advanced hepatocellular carcinoma (HCC). The most commonly involved major vessel is the portal vein; however, approximately 4% of patients with HCC have inferior vena cava (IVC) and/or right atrium (RA) invasion. Although these conditions have dismal prognoses, local treatments have not been regularly administered because they may affect systemic circulation. Owing to recent technological advances, various local treatments including surgery and external radiotherapy have increasingly been performed in these patients. Since irradiating tumorous lesions in the liver while preserving normal tissues is possible and major vessels are relatively resistant to radiation, external radiotherapy has been a feasible palliative modality for treating vessel-invasive HCC. In addition, systemic fatal complications that were initially a cause of concern have become rare after radiotherapy. While invasive procedures such as extracorporeal circulation or hepatic vascular exclusion may be required, pioneering surgeons have performed surgical resections in selected patients and have obtained promising results. Surgery has shown the best survival outcomes compared to other treatment options including radiotherapy, but the possibility of perioperative morbidity should be considered. In addition, a combination of local treatment and novel systemic agents, which demonstrated better survival and response rates than sorafenib, is expected to maximize therapeutic effects. In this review, we have discussed the most recent treatments for HCC with IVC and/or RA involvement and have provided information intended to guide therapeutic decisions and facilitate future research.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE